Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The Final Frontier - Online Remote Trading -- Ignore unavailable to you. Want to Upgrade?

To: cool who wrote (3956)	5/4/1998 2:26:00 PM
From: Leman	Read Replies (1) \| Respond to of 12617

I was right on HYALF Monday May 4, 11:11 am Eastern Time Company Press Release SOURCE: Hyal Pharmaceutical Corporation Solarase(TM) Approved in Germany, Sweden, France and Italy MISSISSAUGA, Ont., May 4 /CNW-PRN/ - Hyal Pharmaceutical Corporation (NASDAQ/NNM: HYALF - news; TSE: HPC - news) announced today that its lead product Solarase has received regulatory approval for marketing in Germany, Sweden, Italy and France, in addition to the previously announced approval for the United Kingdom. Solarase has been shown to be an effective topical therapy for actinic keratosis or sunspots, the forerunner of one of the most common forms of skin cancer - squamous cell carcinoma. Actinic Keratosis is a sun exposure related precancerous skin condition affecting one in six adults worldwide. The current market for various treatments for this condition in the U.S.A. alone is approximately US$240 million per annum. ''This important milestone further validates Hyal's HIT(TM) technology and adds value to Solarase for potential partners,'' said Dr. Zenas B. Noon, Jr., Hyal's President and CEO. ''We also expect to file a submission to the FDA in the third quarter of this year seeking marketing approval for the USA. Hyal is currently seeking marketing approval for Solarase in Canada, Australia and New Zealand.'' Solarase utilizes Hyal's proprietary HIT technology. Compared to other Actinic Keratosis treatments, Solarase is non-invasive, non-scarring and is extremely well tolerated by patients. Hyal received a patent from the United States Patent Office in January 1997 protecting Solarase. Hyal Pharmaceutical Corporation is a drug delivery company engaged in research and development and is seeking worldwide commercialization of pharmaceutical formulations utilizing its proprietary Hyaluronan Induced Targeting (HIT)(TM) Technology and Hyaluronan Improved Liposome Technology (HILT)(TM). This news release may contain forward-looking statements relating to the future performance of Hyal. Forward-looking statements, specifically those concerning future performance, are subject to certain risks and uncertainties, and actual results may differ materially. These risks and uncertainties are detailed from time to time in the Company's filings with the appropriate securities commissions. SOURCE: Hyal Pharmaceutical Corporation